Anti-ITGB3 Polyclonal Antibody 2 is a Rabbit antibody targeting ITGB3. Anti-ITGB3 Polyclonal Antibody 2 can be used in WB,FCM.

IgG

Human,Mouse (predicted:Rat,Dog,Pig,Cow,Horse,Rabbit,Sheep)

1. Sample:
Lane 1: Thyroid gland (Mouse) Lysate at 40 μg
Lane 2: Jurkat (Human) Cell Lysate at 30 μg
Lane 3: Du145 (Human) Cell Lysate at 30 μg
Lane 4: Huvec (Human) Cell Lysate at 30 μg
Primary: Anti-Integrin beta 3 (TMAB-07833) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 100 kD
Observed band size: 110 kD
2. Blank control: HUVEC.
Primary Antibody (green line): Rabbit Anti-Integrin beta 3 antibody (TMAB-07833)
Dilution: 1 μg/Test;
Secondary Antibody: Goat anti-rabbit IgG-FITC
Dilution: 0.5 μg/Test.
Protocol
The cells were incubated in 5% BSA to block non-specific protein-protein interactions for 30 min at room temperature. Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

WB: 1:500-2000; FCM: 1μg/Test

Polyclonal

KLH conjugated synthetic peptide: human Integrin beta 3

Human

ITGB3

Integrin beta-3

Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.